TScan Therapeutics, Inc. (TCRX) Tops Q4 EPS by 9c

TScan Therapeutics, Inc. (NASDAQ: TCRX) reported Q4 EPS of ($0.18), $0.09 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $2.57 million versus the consensus estimate of $2.04 million.

For earnings history and earnings-related data on TScan Therapeutics, Inc. (TCRX) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Full Circle Lithium closes $5.14M private placement
• Boeing lands two U.S. defense contracts worth over $711M